{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:52Z","timestamp":1793946532077,"version":"4.8.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105469","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:05:28Z","timestamp":1783091128000},"page":"105469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy"],"prefix":"10.1016","volume":"226","author":[{"given":"Ting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105469_bib1","first-page":"209","article-title":"Radiotherapy Combination: Insight from Tumor Immune Microenvironment (TIME)","volume":"15","author":"Alimohammadi","year":"2023","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag3187","article-title":"Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2","volume":"8","author":"Arenas-Ramirez","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib3","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.ymthe.2024.06.029","article-title":"Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine","volume":"32","author":"Basnet","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105469_bib4","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.immuni.2023.11.005","article-title":"Stat5 opposes the transcription factor Tox and rewires exhausted CD8+ T cells toward durable effector-like states during chronic antigen exposure","volume":"56","author":"Beltra","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105469_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib6","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13046-024-03238-x","article-title":"Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice","volume":"44","author":"Carbone","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105469_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105469_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105469_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.09.014","article-title":"Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers","volume":"495","author":"Davern","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105469_bib13","article-title":"Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis","author":"David","year":"2011","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib15","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103729","article-title":"The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy","volume":"175","author":"Donlon","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib17","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1538-7445.AM2021-1744","article-title":"Abstract 1744: STK-012, an alpha\/beta selective IL-2 mutein for the activation of the antigen-activated T cells in solid tumor","volume":"81","author":"Emmerich","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105469_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1227143","article-title":"Primary microcephaly gene CENPE is a novel biomarker and potential therapeutic target for non-WNT\/non-SHH medulloblastoma","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104273","article-title":"Stem cell-like memory T cells: A perspective from the dark side","volume":"361","author":"Gao","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/ckj\/sfw068","article-title":"Atypical anti-glomerular basement membrane disease: lessons learned","volume":"9","author":"Glassock","year":"2016","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.critrevonc.2026.105469_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12916-024-03420-0","article-title":"IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer","volume":"22","author":"Guo","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib24","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105469_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011040","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Guo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib26","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jtho.2025.02.026","article-title":"Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)","volume":"20","author":"Hakozaki","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105469_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.trecan.2023.11.008","article-title":"Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy","volume":"10","author":"Hashimoto","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib29","article-title":"Unraveling the anti-tumor effects and molecular mechanisms of hairyvein agrimonia herb in gastric cancer through network pharmacology and experimental validation","volume":"8","author":"He","year":"2025","journal-title":"Cancer Rep."},{"key":"10.1016\/j.critrevonc.2026.105469_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156628","article-title":"A forced marriage of IL-2 and PD-1 antibody nurtures tumor-infiltrating T cells","volume":"132","author":"Holcomb","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2026.105469_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41586-025-09440-x","article-title":"Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells","volume":"649","author":"Hor","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105469_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.immuni.2022.12.012","article-title":"Something old, something new: The marriage of PD-1 and IL-2","volume":"56","author":"Horton","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105469_bib34","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/psp4.70112","article-title":"PD-1-Cis IL-2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1-IL2v)","volume":"14","author":"Hutchinson","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib35","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO-25-01439","article-title":"KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?","volume":"43","author":"Ilson","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib38","doi-asserted-by":"crossref","DOI":"10.26502\/droh.0076","article-title":"Effects of Topoisomerase II alpha Inhibition on Oral Cancer Cell Metabolism and Cancer Stem Cell Function","author":"Kanagasabai","year":"2024","journal-title":"Dent. Res. Oral. Health 7 5865"},{"key":"10.1016\/j.critrevonc.2026.105469_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol. & Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1286116","article-title":"Case report: the effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer","volume":"14","author":"Kian","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib41","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105469_bib43","article-title":"A CD25-chemokine receptor complex initiates noncanonical IL-2 signaling","volume":"302","author":"Lee","year":"2026","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105469_bib44","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1073\/pnas.0909384107","article-title":"IL-2\/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25","volume":"107","author":"L\u00e9tourneau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105469_bib45","article-title":"CXCL12\/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib46","article-title":"Synergistic potential of PD-1 blockade and IL-2 in cancer therapy via targeted bi-functional molecule design","author":"Li","year":"2025","journal-title":"Sci. Bull. (Beijing) S2095-9273(25)008096"},{"key":"10.1016\/j.critrevonc.2026.105469_bib47","article-title":"Synergistic potential of PD-1 blockade and IL-2 in cancer therapy via targeted bi-functional molecule design","author":"Li","year":"2025","journal-title":"Sci. Bull. (Beijing) S2095-9273(25)008096"},{"key":"10.1016\/j.critrevonc.2026.105469_bib48","article-title":"Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy","author":"Li","year":"2020","journal-title":"Sci. Adv. 6 eaay4211."},{"key":"10.1016\/j.critrevonc.2026.105469_bib49","article-title":"Taurine-mediated metabolic immune crosstalk indicates and promotes immunosuppression with anti-PD-1 resistance in bladder cancer","volume":"16","author":"Liang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib50","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1084\/jem.20180749","article-title":"Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma","volume":"216","author":"Liu","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/pcmedi\/pby011","article-title":"Recent updates on cancer immunotherapy","volume":"1","author":"Liu","year":"2018","journal-title":"Precis. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/imm.13723","article-title":"The soluble IL-2 receptor \u03b1\/CD25 as a modulator of IL-2 function","volume":"171","author":"Lokau","year":"2024","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105469_bib53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II\/III DANTE\/IKF-s633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2026.105469_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1873607","article-title":"Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer","volume":"10","author":"Martinez","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105469_bib56","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","article-title":"An engineered IL-2 partial agonist promotes CD8+ T cell stemness","volume":"597","author":"Mo","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105469_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1005","article-title":"Human FOXP3+ T regulatory cell heterogeneity","volume":"7","author":"Mohr","year":"2018","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib58","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3389\/fimmu.2018.02905","article-title":"Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy","volume":"9","author":"Mortara","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2381891","article-title":"Discovery and development of ANV419, an IL-2\/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy","volume":"16","author":"Murer","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.critrevonc.2026.105469_bib61","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i5.104623","article-title":"Treatment strategies targeting the phosphoinositide 3-kinase\/protein kinase B\/mechanistic target of rapamycin pathway against triple-negative breast cancer","volume":"16","author":"Ni","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202418838","article-title":"Bi-Functional Topospecific Nanoparticles to Promote Immune-Tumor Cell Engagement as A New Immunotherapeutic Strategy","volume":"38","author":"Ortu\u00f1o-Bernal","year":"2026","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2026.105469_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004913","article-title":"Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer","volume":"10","author":"Pan","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib64","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ijc.34281","article-title":"CD25: A potential tumor therapeutic target","volume":"152","author":"Peng","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib65","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","article-title":"Simultaneous targeting of PD-1 and IL-2R\u03b2\u03b3 with radiation therapy inhibits pancreatic cancer growth and metastasis","volume":"41","author":"Piper","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105469_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5409","article-title":"Interleukin-2\u2013based therapies in cancer","volume":"14","author":"Raeber","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib67","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.6026\/973206300213035","article-title":"Retrospective analysis of preoperative nutritional status and postoperative complications in gastric cancer surgery","volume":"21","author":"Ranjith","year":"2025","journal-title":"Bioinformation"},{"key":"10.1016\/j.critrevonc.2026.105469_bib68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/CAD.0000000000001705","article-title":"The tetravalent, bispecific properties of FS118, an anti-LAG-3\/PD-L1 antibody, mediate LAG-3 shedding from CD4 + and CD8 + tumor-infiltrating lymphocytes","volume":"36","author":"Reader","year":"2025","journal-title":"Anticancer. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105469_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004991","article-title":"TransCon IL-2 \u03b2\/\u03b3: a novel long-acting prodrug with sustained release of an IL-2R\u03b2\/\u03b3-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","volume":"10","author":"Rosen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib71","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-2502","article-title":"Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab","author":"Sanmamed","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105469_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006409","article-title":"Combination of cancer vaccine with CD122-biased IL-2\/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8+ T cells against tumor","volume":"11","author":"Shimizu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib73","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO-25-00486","article-title":"Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study","volume":"43","author":"Shitara","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib75","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322356121","article-title":"IL-2\/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines","volume":"121","author":"Sobral","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105469_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189277","article-title":"Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies","volume":"1880","author":"Song","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib77","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/oncolo\/oyac048","article-title":"ADXS31142 Immunotherapy \u00b1 Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I\/II KEYNOTE-046 Study","volume":"27","author":"Stein","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105469_bib78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00262-025-04128-7","article-title":"Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms","volume":"74","author":"Sundstrom","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105469_bib79","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","article-title":"Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages","volume":"56","author":"Tichet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105469_bib80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib81","first-page":"4484","article-title":"Dutch Upper Gastrointestinal Cancer Audit Group","volume":"28","author":"Voeten","year":"2021","journal-title":"Failure Cure Patients Undergoing Surgery Gastric Cancer A Nationwide Cohort Study. Ann. Surg. Oncol"},{"key":"10.1016\/j.critrevonc.2026.105469_bib82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non\u2013Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib83","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/JLB.5MR0321-145R","article-title":"Stem cell-like memory T cells: The generation and application","volume":"110","author":"Wang","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib84","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1172\/JCI67008","article-title":"PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells","volume":"123","author":"West","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105469_bib85","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells","volume":"4","author":"Wu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105469_bib86","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40259-026-00769-x","article-title":"Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy","volume":"40","author":"Xu","year":"2026","journal-title":"BioDrugs"},{"key":"10.1016\/j.critrevonc.2026.105469_bib87","article-title":"AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity","volume":"16","author":"Ye","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105469_bib88","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JS9.0000000000002056","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis","volume":"111","author":"Yu","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105469_bib89","article-title":"Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center","volume":"14","author":"Zhao","year":"2024","journal-title":"Open. -Label. Single-Arm. phase II Trial Clin. &amp Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105469_bib90","doi-asserted-by":"crossref","first-page":"446","DOI":"10.21147\/j.issn.1000-9604.2025.03.12","article-title":"Tumor-educated cells in tumor microenvironment: Key drivers of immunotherapy resistance","volume":"37","author":"Zou","year":"2025","journal-title":"Chin. J. Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:47:39Z","timestamp":1793944059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":90,"alternative-id":["S1040842826003562"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105469","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105469"}}